Sensorion announces completion of patient enrollment and dosing in Seliforant phase 2a study. pdfRead

Sensorion enters into exclusive negotiations with Pasteur Institute for hearing loss Gene Therapy programs. pdfRead

Sensorion announces presentation of SENS-401 poster at society for Neuroscience 2018 annual meeting. pdfRead

Sensorion Reports Pipeline Update and First-Half-Year 2018 Results. Re-design of SENS-111 Study. pdfRead

Sensorion Reports Pipeline Update and First-Half-Year 2018 Results

Re-design of SENS-111 Study

Sensorion Announces Publication of Seliforant Phase 1 Study Data in the British Journal of Clinical Pharmacology. pdfRead

Next events